MedTrace Logo

Dyspareunia and Central Sensitization

NCT03216330 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2026-04-08

Study results available
· View outcomes & findings →

Summary

Background: Endometriosis affects 10% of reproductive aged females, and can have a negative impact on sexual quality of life. Endometriosis can cause pelvic pain with deep penetration during intercourse, as well as other sexual and non-sexual pains. This study will allow us to determine if an increase in sexual pain is related to central sensitization.

Purpose: The purpose of this study is to determine if there is an association between the severity of sexual pain and central sensitization in women with endometriosis.

Measurement tools: Data will be collected from the Clinic's Data Registry, an online questionnaire, a quantitative sensory test (QST) to measure pain-pressure threshold (PPT) as a marker of central sensitization, and daily entry to an online survey.

Primary Hypothesis: Central sensitization (measured by lower pain-pressure threshold) will be associated with an increased severity of deep dyspareunia, as well as a tenderness of the bladder/pelvic floor and depression, in women with endometriosis.

Conditions

  • Endometriosis
  • Central Sensitisation
  • Dyspareunia

Interventions

OTHER

No Intervention

There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.

Sponsors & Collaborators

  • BC Women's Hospital & Health Centre

    lead OTHER

Principal Investigators

  • Paul Yong, MD/PhD · BC Children's and Women's Hospital

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-19
Primary Completion
2019-04-01
Completion
2019-04-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03216330 on ClinicalTrials.gov